This paper is in the following e-collection/theme issue:

Theme issue 2021: Outbreaks and Public Health Surveillance research in the Eastern Mediterranean Region (23) Outbreak and Pandemic Preparedness and Management (1727) Infectious Diseases (non-STD/STI) (1575) Innovative Methods in Public Health and Surveillance (332) Hygiene and Infection Prevention (317) JMIR Theme Issue: COVID-19 Special Issue (2452) Theme Issue: Novel Coronavirus (COVID-19) Outbreak Rapid Reports (1517)

Published on in Vol 7, No 5 (2021): May

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/27609, first published .
Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome

Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome

Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome

Authors of this article:

Sabahat Ali1 Author Orcid Image ;   Sundas Khalid2 Author Orcid Image ;   Maham Afridi3 Author Orcid Image ;   Samar Akhtar4 Author Orcid Image ;   Yousef S Khader5 Author Orcid Image ;   Hashaam Akhtar4 Author Orcid Image
Article Authors Cited by (3) Tweetations (1) Metrics

Journals

  1. Vulturar D, Neag M, Vesa Ș, Maierean A, Gherman D, Buzoianu A, Orăsan O, Todea D. Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection. International Journal of Molecular Sciences 2022;23(22):14462 View
  2. Edinoff A, Alpaugh E, Newgaard O, Wajid I, Klapper R, Cornett E, Kaye A, Iyer P, Kaye A. Tocilizumab for Severe COVID-19 Infection and Multisystem Inflammatory Syndrome in Adults and Children. Life 2023;13(4):889 View
  3. Al-Mistarehi A, El-Akawi S, Kheirallah K, Bani Ata E, Zaitoun K, Khassawneh A, Jarrah A, Alzoubi H, Al-Azzam S, Karasneh R, Altawalbeh R, Khassawneh B. Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study. Cureus 2024 View